{
    "paper_id": "f7291d8bba89ea7cf0f38692d21a0ee2c8e20fb4",
    "metadata": {
        "title": "The ProTides Boom",
        "authors": [
            {
                "first": "Youcef",
                "middle": [],
                "last": "Mehellou",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Birmingham",
                    "location": {
                        "addrLine": "Edgbaston",
                        "postCode": "B15 2TT",
                        "country": "UK"
                    }
                },
                "email": "y.mehellou@bham.ac.uk"
            },
            {
                "first": "Dedicatedtoprof",
                "middle": [
                    "Chris"
                ],
                "last": "Mcguigan",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Birmingham",
                    "location": {
                        "addrLine": "Edgbaston",
                        "postCode": "B15 2TT",
                        "country": "UK"
                    }
                },
                "email": ""
            },
            {
                "first": "Y",
                "middle": [],
                "last": "Mehellou",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Birmingham",
                    "location": {
                        "addrLine": "Edgbaston",
                        "postCode": "B15 2TT",
                        "country": "UK"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [
        {
            "text": "Phosphate prodrug strategies have been successfully used in the discoveryo fv ariousn ucleotide therapeutics that are currently in daily clinical use for the treatment of viral infections, in particular,h epatitisBand C( HBV and HCV,r espectively) and HIV. [1] Over the last few years, the 'ProTide' technology-pioneered by Chris McGuigan (CardiffU niversity,U K)-has emergeda sapowerful strategy in the discovery of nucleotide therapeutics. [2] Indeed,t his technology was used in the successfuld iscovery and development of two FDA-approved Pro-Tides, Sovaldia nd tenofovir alafenamide. The pipelines of severalp harma and biotech companies seem to be stocked with as election of ProTides, some of whicha re currently in phase III clinical trials, whilet here is an increasing number of reports on ProTides undergoing preclinical studies. Collectively, these reflect aP roTides boom that could, in the future, be translatedi nto the approval of more ProTides to treat viral infections and cancer.",
            "cite_spans": [
                {
                    "start": 257,
                    "end": 260,
                    "text": "[1]",
                    "ref_id": null
                },
                {
                    "start": 442,
                    "end": 445,
                    "text": "[2]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "The in vivo activation of many antiviral anda nticancer nucleosides involves phosphorylation into their active di-or triphosphate counterparts. [3] Amongt he three kinase-dependent phosphorylations teps required for the bioactivation of this class of therapeutics, the first phosphorylations tep that converts nucleosides into their 5'-O-monophosphate derivatives is often found to be the rate-limiting step. [4] To overcome this, numerous strategies that deliver nucleoside 5'-O-monophosphates into cells have been developed. [1] Nowadays, one of the most applied phosphate prodrug approaches is the ProTide technology.T he development [2] of this technology startedb y maskingt he 5'-O-monophosphate groups of therapeutic nucleosides with simple dialkyl and then haloalkyl groups.H owever,t hese attempts did not lead to improved biological activity,m ost likely due to the inability of these maskingg roups to be hydrolyzed in vivo to releaset he nucleoside monophosphate, which can be subsequently furtherp hosphorylated to the actives pecies. Next, McGuigan and co-workerss ynthesized alkyloxy and haloalkylp hosphoramidate prodrugs, and these showedb etter activities than their parentn ucleosides. [5] This was the first breakthrough in the development of ProTides and provided evidence that masking of phosphate groups with biocleavable motifs may yield an effective prodrug system for the delivery of therapeutic nucleoside monophosphates. These initial studies identified l-alanine as as uperiora mino acid in the alkyloxy phosphoramidates,a no bservation that has informed recent drug discoveryp rograms that yielded FDA-approvedd rugs. [5b] Encouraged by this, the phosphate group was masked with two amino acid esters. Back then, this was found not to be beneficial as the prodrugs were largely inactive. Diarylp hosphates weres tudied next, and these showed very good activity.H ence,t he McGuigan lab combined the amino acid ester from the alkyloxy and haloalkyl phosphoramidates and the aryl masking group to generate aryloxy triester phosphoramidates. [6] These were found to be superior in the delivery of therapeutic nucleoside 5'-O-monophosphates.S ince then, the masking of the phosphate group with an amino acid ester and an aryl motif, nowadays known as the ProTide technology,h as becomea na pproved prodrug strategy in the discovery of nucleotide therapeutics. The mechanismb yw hich the ProTides are metabolized in vivo to release the nucleoside monophosphate is believed to proceed through the action of two enzymes:a ne sterase, such as cathepsin A, [7] and ap hosphoramidase-type enzyme, such as hint-1, [8] as illustrated in Scheme 1. [2] ProTides as clinical candidates and drugs",
            "cite_spans": [
                {
                    "start": 144,
                    "end": 147,
                    "text": "[3]",
                    "ref_id": null
                },
                {
                    "start": 527,
                    "end": 530,
                    "text": "[1]",
                    "ref_id": null
                },
                {
                    "start": 637,
                    "end": 640,
                    "text": "[2]",
                    "ref_id": null
                },
                {
                    "start": 2069,
                    "end": 2072,
                    "text": "[6]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 2578,
                    "end": 2581,
                    "text": "[7]",
                    "ref_id": null
                },
                {
                    "start": 2633,
                    "end": 2636,
                    "text": "[8]",
                    "ref_id": null
                },
                {
                    "start": 2665,
                    "end": 2668,
                    "text": "[2]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Abstract"
        },
        {
            "text": "To date, at least ten ProTides have reached clinical trials and have been investigated as treatments for viral infections and cancer (Figure 1 ). The McGuigan research group discovered and developed the anti-HCV agent INX-189, aP roTide of 6-Omethyl-2'-C-methyl guanosine (1). [9] At that time, this compoundw as the most potent inhibitor of HCV replication in cell-based replication assays (EC 50 = 0.01 mm,E C 90 = 0.04 mm, CC 50 = 7 mm). Critically, it generated significantly higher levels of the 6-O-methyl-2'-C-methyl guanosine triphosphate than",
            "cite_spans": [
                {
                    "start": 277,
                    "end": 280,
                    "text": "[9]",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 133,
                    "end": 142,
                    "text": "(Figure 1",
                    "ref_id": null
                }
            ],
            "section": "Abstract"
        },
        {
            "text": "The maskingo fn ucleoside phosphate and phosphonate groups by an aryl motif and an amino acid ester,n owadays known as the 'ProTide' technology, has provent ob ee ffective in the discoveryo fn ucleotide therapeutics. Indeed, this technology,w hich was invented by Chris McGuigan in the early 1990s, has inspired the discovery of two FDA-approved antivi-ral nucleotide drugs, and many more are currently undergoing (pre)clinical development.T he usefulness of this technology in the discoveryo fn ucleotide therapeuticsi ss howcased in this Highlight by discussing the ProTides development and the various ProTides that have reached clinical trials.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Abstract"
        }
    ],
    "body_text": [
        {
            "text": "Phosphate prodrug strategies have been successfully used in the discoveryo fv ariousn ucleotide therapeutics that are currently in daily clinical use for the treatment of viral infections, in particular,h epatitisBand C( HBV and HCV,r espectively) and HIV. [1] Over the last few years, the 'ProTide' technology-pioneered by Chris McGuigan (CardiffU niversity,U K)-has emergeda sapowerful strategy in the discovery of nucleotide therapeutics. [2] Indeed,t his technology was used in the successfuld iscovery and development of two FDA-approved Pro-Tides, Sovaldia nd tenofovir alafenamide. The pipelines of severalp harma and biotech companies seem to be stocked with as election of ProTides, some of whicha re currently in phase III clinical trials, whilet here is an increasing number of reports on ProTides undergoing preclinical studies. Collectively, these reflect aP roTides boom that could, in the future, be translatedi nto the approval of more ProTides to treat viral infections and cancer.",
            "cite_spans": [
                {
                    "start": 257,
                    "end": 260,
                    "text": "[1]",
                    "ref_id": null
                },
                {
                    "start": 442,
                    "end": 445,
                    "text": "[2]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "The in vivo activation of many antiviral anda nticancer nucleosides involves phosphorylation into their active di-or triphosphate counterparts. [3] Amongt he three kinase-dependent phosphorylations teps required for the bioactivation of this class of therapeutics, the first phosphorylations tep that converts nucleosides into their 5'-O-monophosphate derivatives is often found to be the rate-limiting step. [4] To overcome this, numerous strategies that deliver nucleoside 5'-O-monophosphates into cells have been developed. [1] Nowadays, one of the most applied phosphate prodrug approaches is the ProTide technology.T he development [2] of this technology startedb y maskingt he 5'-O-monophosphate groups of therapeutic nucleosides with simple dialkyl and then haloalkyl groups.H owever,t hese attempts did not lead to improved biological activity,m ost likely due to the inability of these maskingg roups to be hydrolyzed in vivo to releaset he nucleoside monophosphate, which can be subsequently furtherp hosphorylated to the actives pecies. Next, McGuigan and co-workerss ynthesized alkyloxy and haloalkylp hosphoramidate prodrugs, and these showedb etter activities than their parentn ucleosides. [5] This was the first breakthrough in the development of ProTides and provided evidence that masking of phosphate groups with biocleavable motifs may yield an effective prodrug system for the delivery of therapeutic nucleoside monophosphates. These initial studies identified l-alanine as as uperiora mino acid in the alkyloxy phosphoramidates,a no bservation that has informed recent drug discoveryp rograms that yielded FDA-approvedd rugs. [5b] Encouraged by this, the phosphate group was masked with two amino acid esters. Back then, this was found not to be beneficial as the prodrugs were largely inactive. Diarylp hosphates weres tudied next, and these showed very good activity.H ence,t he McGuigan lab combined the amino acid ester from the alkyloxy and haloalkyl phosphoramidates and the aryl masking group to generate aryloxy triester phosphoramidates. [6] These were found to be superior in the delivery of therapeutic nucleoside 5'-O-monophosphates.S ince then, the masking of the phosphate group with an amino acid ester and an aryl motif, nowadays known as the ProTide technology,h as becomea na pproved prodrug strategy in the discovery of nucleotide therapeutics. The mechanismb yw hich the ProTides are metabolized in vivo to release the nucleoside monophosphate is believed to proceed through the action of two enzymes:a ne sterase, such as cathepsin A, [7] and ap hosphoramidase-type enzyme, such as hint-1, [8] as illustrated in Scheme 1. [2] ProTides as clinical candidates and drugs",
            "cite_spans": [
                {
                    "start": 144,
                    "end": 147,
                    "text": "[3]",
                    "ref_id": null
                },
                {
                    "start": 409,
                    "end": 412,
                    "text": "[4]",
                    "ref_id": null
                },
                {
                    "start": 527,
                    "end": 530,
                    "text": "[1]",
                    "ref_id": null
                },
                {
                    "start": 637,
                    "end": 640,
                    "text": "[2]",
                    "ref_id": null
                },
                {
                    "start": 1205,
                    "end": 1208,
                    "text": "[5]",
                    "ref_id": null
                },
                {
                    "start": 1648,
                    "end": 1652,
                    "text": "[5b]",
                    "ref_id": null
                },
                {
                    "start": 2069,
                    "end": 2072,
                    "text": "[6]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 2578,
                    "end": 2581,
                    "text": "[7]",
                    "ref_id": null
                },
                {
                    "start": 2633,
                    "end": 2636,
                    "text": "[8]",
                    "ref_id": null
                },
                {
                    "start": 2665,
                    "end": 2668,
                    "text": "[2]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "To date, at least ten ProTides have reached clinical trials and have been investigated as treatments for viral infections and cancer ( Figure 1 ). The McGuigan research group discovered and developed the anti-HCV agent INX-189, aP roTide of 6-Omethyl-2'-C-methyl guanosine (1). [9] At that time, this compoundw as the most potent inhibitor of HCV replication in cell-based replication assays (EC 50 = 0.01 mm,E C 90 = 0.04 mm, CC 50 = 7 mm). Critically, it generated significantly higher levels of the 6-O-methyl-2'-C-methyl guanosine triphosphate than",
            "cite_spans": [
                {
                    "start": 278,
                    "end": 281,
                    "text": "[9]",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 135,
                    "end": 143,
                    "text": "Figure 1",
                    "ref_id": "FIGREF1"
                }
            ],
            "section": ""
        },
        {
            "text": "The maskingo fn ucleoside phosphate and phosphonate groups by an aryl motif and an amino acid ester,n owadays known as the 'ProTide' technology, has provent ob ee ffective in the discoveryo fn ucleotide therapeutics. Indeed, this technology,w hich was invented by Chris McGuigan in the early 1990s, has inspired the discovery of two FDA-approved antivi-ral nucleotide drugs, and many more are currently undergoing (pre)clinical development.T he usefulness of this technology in the discoveryo fn ucleotide therapeuticsi ss howcased in this Highlight by discussing the ProTides development and the various ProTides that have reached clinical trials. the parent nucleoside and had ah alf-life of > 24 h. Given the excellent pharmacokinetics (PK) and pharmacodynamics (PD) profiles of INX-189, it was chosen as ac linical candidate that was then developed by Inhibitex Inc. [10] Followings uccessful early clinicalr esults, INX-189w as acquired by Bristol-Myers Squibb (BMS) ands tudied in phase III clinical trials in combination with daclatasvir,a nother anti-HCV experimentald rug of BMS. However,c ardiotoxicity was observed, andf urtherd evelopment was suspended. [11] Other ProTides for the treatment of HCV,p articularly PSI-353661( 2) [12] and PSI-7977 (3), [13] proceeded to clinicale valuation. PSI-353661 is aP roTide of 6-O-methyl-2'-deoxy-2'-fluoro-2'-C-methylguanosine, whereas PSI-7977 is aP roTide of 2'deoxy-2'-fluoro-2'-C-methyluridine. Both compounds showed potent anti-HCV activity throughe fficient delivery of the parentn ucleosides 5'-O-monophosphates. As ar esult of the impressive early data from the clinicalt rials of theset wo agents, they were acquiredb yG ilead Sciences, Inc. Out of the two compounds,P SI-7977, which subsequently became GS-7977, successfully completed clinical evaluations and became known as sofosbuvir (Sovaldi TM ), the first ProTide approved for clinicaluse against HCV.",
            "cite_spans": [
                {
                    "start": 871,
                    "end": 875,
                    "text": "[10]",
                    "ref_id": null
                },
                {
                    "start": 1166,
                    "end": 1170,
                    "text": "[11]",
                    "ref_id": null
                },
                {
                    "start": 1240,
                    "end": 1244,
                    "text": "[12]",
                    "ref_id": null
                },
                {
                    "start": 1263,
                    "end": 1267,
                    "text": "[13]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "GS-5734 (4) [14] is a C-nucleoside ProTide, which is currently undergoing phase Ic linical trials for the treatment of Ebola. [14] Preclinical data showedt hat GS-5734 exerts potent antiviral activity against variants of the Ebola virus (EBOV). The ProTide showed potent inhibition of EBOV replication (EC 50 = 0.06 to 0.14 mm), while the parent C-nucleoside was not as effective (EC 50 :0 .77 to > 20 mm). Impressively, in rhesus monkeys infected with EBOV, once-daily intravenous administration of GS-5734 led to significant suppression of EBOV replication and 100 %p rotection of infected animals against lethal disease.G S-5734 also showed promisingi nhibition of the replication of other pathogenic RNA viruses, such as arenaviruses, filoviruses, and coronaviruses, indicating the wide-spectrum of activity of this ProTide.",
            "cite_spans": [
                {
                    "start": 12,
                    "end": 16,
                    "text": "[14]",
                    "ref_id": null
                },
                {
                    "start": 126,
                    "end": 130,
                    "text": "[14]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "GS-7340 (5), [15] aP roTide of the acyclic nucleoside phosphonate tenofovir,o fw hich the oral prodrug, tenofovir disoproxil, Scheme1.Postulated mechanism of the in vivo metabolism of the ProTides to release nucleoside monophosphates. www.chemmedchem.org is FDA-approvedf or HIV therapy,e xhibitedi mproved anti-HIV activity and better in vivo stability than tenofovir. Impressively, the ProTide GS-7340 generated 10-to 30-foldh igherl evels of tenofovir and itsphosphorylated metabolites following incubation of peripheral blood mononuclear cells compared with tenofovir disoproxil and tenofovir,r espectively. [16] Although GS-7340 is similart ot he FDA-approved tenofovir disoproxil, it is more potent,a nd thus in phase III clinical studies therapeutic effects were achieveda tl ower doses with fewer incidences of side effects. In late 2015, GS-7340, now known as tenofovir alafenamide, was approved in combination with other anti-HIV agents for the treatment of HIV-1i nfection.",
            "cite_spans": [
                {
                    "start": 13,
                    "end": 17,
                    "text": "[15]",
                    "ref_id": null
                },
                {
                    "start": 612,
                    "end": 616,
                    "text": "[16]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "NUC-1031 (6) [17] is an anticancer ProTide that was discovered by the McGuigan group and is currently being developed by NuCana Biomed Ltd. It is ap rodrug of the FDA-approved anticancer drug gemcitabine (Gemzar TM ). This compound overcame three resistance mechanisms that limit the efficacy of the parentn ucleoside gemcitabine. Results from phase I/II clinical trials showed that NUC-1031i se ffective against aw ide range of cancers and was well-toleratedb yp atients.Impressively,f ive out of 68 patients achieved tumor shrinkage of ! 30 %, while an additional 33 patients had achieveds table disease. NuCana is also pushing forward the clinical development of NUC-3373, [18] aP roTide of 5-fluoro-2'-deoxyuridine (FUDR) [structure not shown].",
            "cite_spans": [
                {
                    "start": 13,
                    "end": 17,
                    "text": "[17]",
                    "ref_id": null
                },
                {
                    "start": 676,
                    "end": 680,
                    "text": "[18]",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "At least afurtherfour ProTides were reported to have undergone clinicale valuation, that is, thymectacin (7)f or cancer, stampidine (8)a nd GS-9131 (9)f or HIV;a nd GS-6620 (10)f or HCV.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "The plethora of ProTides that have been, are still undergoing, or have successfully completed clinicalt rials clearly highlights the effectiveness of this technology to deliver nucleotide therapeutics. Coupling this to the largen umber of ProTides that are currently undergoing preclinical evaluation, it is safe to say that more ProTides will progress into clinical studies, increasingt he chances of more ProTides being approved in the future to treat viral infections and cancer. This has been made possible by the pioneering work of Prof. ChrisM cGuigan that started in the early 1990s, and which years later yielded the ProTide technology as we know it today.S ince its development, the ProTide technology has been widely adopted and adaptedb ya cademic research groups, as well as small and large pharmaceutical companies to discover new medicines that have already improved treatment outcomes and consequently the quality of life of many patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Keywords: nucleosides \u00b7 nucleotides \u00b7 phosphorylation \u00b7 prodrugs \u00b7 protides",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Antiviral Res",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Mcguigan",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "N"
                    ],
                    "last": "Pathirana",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Mahmood",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "G"
                    ],
                    "last": "Evine",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Hay",
                    "suffix": ""
                }
            ],
            "year": 1992,
            "venue": "",
            "volume": "17",
            "issn": "",
            "pages": "311--321",
            "other_ids": {
                "DOI": [
                    "10.1016/0166-3542(92)90026-2"
                ]
            }
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "harmacy, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, B15 2TT (UK) E-mail:y.mehellou@bham.ac.uk The ORCID identification number(s) for the author(s) of this article can be found under http://dx.doi.org/10.1002/cmdc.201600156.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Structures of as election of ProTides that havereachedclinical trials and those that have been approved by the FDA.ChemMedChem 2016, 11,1 114-1116",
            "latex": null,
            "type": "figure"
        }
    },
    "back_matter": []
}